

Author Index

- Abdollahi M
 3(1), 113–117
 3(1), 119–123
 3(3), 413–419
 Abruzzo GK
 3(4), 521–526
 Afshari M
 3(1), 119–123
 Agnese V
 3(3), 401–407
 Agrawal A
 3(4), 475–484
 Ahmed M
 3(1), 1–3
 Aidietis A
 3(1), 125–138
 Akman A
 3(1), 139–151
 Alpsoy E
 3(1), 139–151
 Amsden GW 3
 (3), 359–365
 Antoniou KM
 3(1), 163–174
 Arora S
 3(3), 409–412
 Astanehi-Asghari F
 3(1), 119–123
 Augello C
 3(3), 401–407
 Badalamenti Ge
 3(3), 401–407
 Baiaty A
 3(1), 113–117
 Barnett AH
 3(3), 339–348
 Barua JM
 3(3), 397–400
 Bazan V
 3(3), 401–407
 Beaulieu J
 3(1), 69–78
 Beck M
 3(1), 9–17
 Bellary S
 3(3), 339–348
 Born L
 3(1), 153–162
 Bouros D
 3(1), 163–174
 Brook NR
 3(3), 421–430
 Brown D
 3(4), 535–545
 Brunton S
 3(4), 527–534
 Bubb C
 3(3), 409–412
 Cackett P
 3(3), 401–402
 Calò V
 3(3), 401–407
 Cameron JR
 3(3), 401–402
 Cappellini
 3(4), 453–460
 Cascio S
 3(3), 401–407
 Cefuroxime
 3(4), 527–534
 Chalmers LM
 3(4), 495–498
 Chamberlain MC
 3(4), 495–498
 Chowdhary SA
 3(4), 495–498
 Clarke A
 3(3), 349–357
 Colquhoun AJ
 3(3), 421–430
 Deshmokh M
 3(3), 409–412
 DiBaise JK
 3(1), 55–67
 Dieter RS
 3(1), 1–3
 3(4), 517–520
 Dupont C
 3(1), 69–78
 Eftekhari B
 3(3), 413–419
 Eftekhari R
 3(3), 413–419
 El-Atat F
 3(3), 409–412
 Ellegard EK
 3(1), 89–92
 Ellegard LH
 3(1), 89–92
 Esmaily H
 3(3), 413–419
 Flattery AF
 3(4), 521–526
 Foulkes R
 3(4), 535–545
 Fricano S
 3(3), 401–407
 Gauthier GM
 3(4), 517–520
 Gebbi N
 3(3), 401–407
 Gebhardt MC
 3(4), 499–508
 Gebreegziabher Y
 3(3), 409–412
 Geriniere L
 3(3), 367–378
 Ghaffarzadeh M
 3(3), 413–419
 Ghameinezhad S
 3(1), 113–117
 Gill CJ
 3(4), 521–526
 Giordano A
 3(3), 401–407
 Gliwa A
 3(3), 409–412
 Green MR
 3(4), 495–498
 Gregorio V
 3(3), 401–407
 Hadidi E
 3(3), 413–419
 Halmesmaki KH
 3(4), 509–516
 Harmon DC
 3(4), 499–508
 Hehmat R
 3(1), 119–123
 Hickey EJ
 3(4), 521–526
 Hornicek FJ
 3(4), 499–508
 Hosseinezhad A
 3(1), 119–123
 Hunt MA
 3(1), 97–112
 Hurskainen RA
 3(4), 509–516
 Ikram S
 3(1), 1–3
 Jahke K
 3(1), 97–112
 Jankovic J
 3(3), 349–357
 Joseph L
 3(3), 409–412
 Khajavi MR
 3(3), 413–419
 Kollias G
 3(4), 535–545
 Kraemer DF
 3(1), 97–112
 Larijani B
 3(1), 119–123
 Lebert F
 3(1), 93–96
 Lee AYY
 3(4), 461–474
 Lemieux P
 3(1), 69–78
 Lip GYH
 3(4), 445–448
 Lip PL
 3(3), 431–438
 Lombardi KM
 3(4), 495–498
 Malekiran AA
 3(1), 113–117
 Mankin HJ
 3(4), 499–508
 Marinskis G
 3(1), 125–138
 Maron L
 3(1), 97–112
 McFarlane SI
 3(3), 409–412
 3(3), 329–333
 Mellish D
 3(3), 409–412
 Mellon J
 3(3), 421–430
 Menon VJK
 3(3), 431–438
 Misura AS
 3(4), 521–526
 Miyasaka N
 3(3), 379–378
 Mohammadirad A
 3(1), 113–117
 3(1), 119–123
 Mojtahedzadeh M
 3(3), 413–419
 Mojtahedi A
 3(1), 119–123
 Morris B
 3(3), 401–402
 Muldoon LL
 3(1), 97–112
 Najafi A
 3(3), 413–419
 Nanjundappa A
 3(1), 1–3
 3(4), 517–520
 Napoli L
 3(3), 401–407
 Nesbitt A
 3(4), 535–545
 Neuwelt EA
 3(1), 97–112
 Nicasio J
 3(3), 409–412
 Nikfar S
 3(3), 413–419
 Orbay P
 3(1), 97–112

APPENDICES

Cumulative indices for 2006

Ormerod AD 3(3), 439–450	Tzouveleakis A 3(1), 163–174	AIR system (see inhaled human insulin)	Azimilide 3(4), 445–448
Paavonen JA 3(4), 509–516	Vazquez JA 3(1), 39–54	AIR® (see inhaled human insulin)	Azithromycin 3(3), 359–365
Pacanowski Jr J 3(1), 1–3	Vigano O 3(1), 79–88	Aldosterone receptor blockers 3(1), 125–138	3(4), 527–534
Paknejad MH 3(3), 413–419	Watson T 3(4), 445–448	Alefacept 3(3), 439–450	Azoles 3(1), 39–54
Phillips SD 3(1), 153–162	Weir N 3(4), 535–545	Alteplase 3(1), 163–174	Aztreonam 3(1), 163–174
Popplewell A 3(4), 535–545	Whorwell P 3(4), 475–484	Alemtuzumeb 3(4), 535–545	β-blocker 3(1), 125–138
Ranjbar A 3(1), 113–117	Wolff MR 3(4), 517–520	Aluminium acetate 3(1), 139–151	3(1), 119–123
Rajpara SM 3(3), 439–450	Woo PN 3(3), 439–450	Amiodarone 3(1), 125–138	3(4), 445–448
Rezaie A 3(1), 119–123	Wyndaele JJ 3(4), 485–494	Amlexanox 3(1), 139–151	β-lactoglobulin 3(1), 69–78
Rouini MR 3(3), 413–419	Zamani MJ 3(3), 413–419	Amoxicilin 3(4), 527–534	β-lactotensin 3(1), 69–78
Rundek T 3(3), 329–333	Zamani H 3(1), 113–117	Amphetamine 3(1), 19–38	Benzatin penicillin 3(1), 139–151
Rusconi S 3(1), 79–88	Zinga D 3(1), 153–162	Amphotericin B 3(1), 39–54	Benzylamine 3(1), 139–151
Russo A 3(3), 401–407		Amprenavir (APV) 3(1), 79–88	Bilateral angle-closure glaucoma 3(3), 421–430
Sahraian MA 3(3), 413–419		Angiotensin-converting enzyme inhibitors 3(1), 125–138	BILA-2185 BS 3(1), 79–88
Santini D 3(3), 401–407	Compound Index	Anidulafungin 3(1), 39–54	Bovine serum albumin 3(1), 69–78
Schwartz J RL 3(3), 379–396	2,4,6-tripyrindyl-S-triazine 3(1), 113–117	Anthracycline 3(1), 97–112	BR96-DOX 3(1), 97–112
Scoppettuolo E 3(3), 401–402	2-thiobarbituric acid 3(1), 113–117	Antidepressants 3(1), 19–38	Bupropion 3(1), 19–38
Shantsila E 3(4), 445–448	5-fluorouracil 3(1), 97–112	Anti-HIV-1 3(1), 79–88	3(1), 153–162
Shatzkes J 3(3), 409–412	^{99m} Tc-glucoseheptonate 3(1), 97–112	Antiangiogenic agents 3(3), 431–438	Burow's solution 3(1), 139–151
Shergill IS 3(3), 397–400	^{99m} Tc-albumin 3(1), 97–112	Antihyperglycemic therapy 3(3), 339–348	Capecitabine 3(1), 97–112
Singh J 3(3), 401–402	α-lactalbumin	Antihypertensives 3(1), 19–38	Carbamazepine 3(1), 39–54
Sisto PS 3(3), 401–407	Acetylcholinesterase 3(1), 93–96	Antipseudomonal penicillins 3(1), 163–174	Carbapenems 3(1), 163–174
Soleimani V 3(3), 413–419	Acute brain injury 3(3), 413–419	Antipseudomonal quinolones 3(1), 163–174	Cataplexy 3(3), 389–396
Souquet PJ 3(3), 367–378	Acute urinary retention 3(3), 421–430	Antitumor necrosis factor-α 3(1), 139–151	Catapres® (see clonidine)
Spitali M 3(4), 535–545	Adalimumab 3(3), 379–387	Arixtra® 3(4), 461–474	Cephalosporins 3(1), 163–174
Stephens S 3(4), 535–545	Adriamycin 3(1), 97–112	Armodafinil 3(3), 389–396	Certolizumab pegol 3(4), 535–545
Tatum M 3(3), 359–365	Aerodose® (see inhaled human insulin)	Atazanavir 3(1), 79–88	Cetuximab 3(3), 421–430
Tuppurainen MT 3(4), 509–516	AERx® (see inhaled human insulin)	Athwal D 3(4), 535–545	Chemotherapy 3(3), 421–430
Turgay A 3(1), 19–38	AG-001859 3(1), 79–88	Atomoxetine hydrochloride 3(1), 19–38	Chlorambucil 3(1), 139–151
Tyson RM 3(1), 97–112	AG1478 3(3), 421–430	Azathioprine 3(1), 139–151	
	Age-related macular degeneration 3(3), 431–438		

Chloramphenicol	Deferiprone	Etoposide phosphate	3(3), 379–387
3(4), 521–526	3(4), 453–460	3(1), 97–112	3(4), 535–545
Chlorhexidine	Dapsone	Excessive sleepiness	Inhaled human insulin
3(1), 139–151	3(1), 139–151	3(3), 389–396	3(3), 339–348
Cholinergic acetyltransferase	Desferal®	Exjade®	Insufflation
3(1), 93–96	3(4), 453–460	3(4), 453–460	3(3), 403–407
Cholinesterase inhibitors	Desipramine	Exubera® (see inhaled human insulin)	Interferon
3(1), 93–96	3(1), 19–38	First-generation HIV–1 protease	3(1), 139–151
Choroidal neovascularization3(3),	Dexamethasone	inhibitors	Intracerebral hemorrhage
431–438	3(1), 39–54	3(1), 79–88	3(3), 413–419
<i>Cinnamomum zeylanicum</i>	3(1), 69–78	Flecainide	Intravenous aminopenicillin
3(1), 113–117	Dexedrine® (see dextroamphermine)	3(4), 445–448	3(1), 163–174
Ciprofloxacin	Dextroamphermine	Fluoxetine	Iressa® (see Gefitinib)
3(1), 163–174	3(1), 19–38	3(1), 19–38	Itraconazole
Cisapride	Diabetes mellitus	3(1), 153–162	3(1), 39–54
3(4), 475–484	3(3), 329–333	Fluvoxamine	Keloides
Cisplatin	3(3), 339–348	3(1), 93–96	3(4), 527–534
3(1), 97–112	Diclofenac	3(1), 153–162	Lactoferrin
3(3), 367–378	3(1), 139–151	Focalin® (see psychostimulants)	3(1), 69–78
Citalopram	Digoxin	Fondaparinox	Lapatinib
3(1), 153–162	3(4), 445–448	3(4), 461–474	3(1), 97–112
Clindamycin	Dihydrotestosterone	Fragmin®	3(3), 421–430
3(1), 163–174	3(3), 397–400	3(4), 461–474	Laronidase
Clonazepam	Dithiobis–2–nitrobenzoic acid	Galsulfase	3(1), 9–17
3(1), 153–162	3(1), 113–117	3(1), 9–17	Levamisole
Clonidine	DMP 450® (see mozenavir)	Gemcitabine	3(1), 139–151
3(1), 19–38	Docetaxel	3(1), 97–112	Levodopa
CNS stimulants	3(1), 97–112	GI198745 (see Dutasteride)	3(3), 349–357
3(3), 389–396	3(3), 367–378	Glibenclamide	Lidocaine
Colchicine	Doxorubicin	3(3), 339–348	3(1), 139–151
3(1), 139–151	3(1), 97–112	Glutamine	Linezolid
Concerta® (see psychostimulants)	Doxycycline	3(1), 55–67	3(4), 521–526
Coronary artery disease	3(3), 359–365	Glutathione	Liposomal doxorubicin
3(3), 329–333	Dronedrone	3(1), 113–117	3(1), 97–112
Corticosteroids	3(4), 445–448	Glycyl–leucyl–phenylalanine	Listerine
3(1), 139–151	Ductal fluid	3(1), 69–78	3(1), 139–151
CP–358–774	3(3), 403–407	Guanfacine	Lopinavir
3(3), 421–430	Ductal lavage	3(1), 19–38	3(1), 79–88
Cremophor EL	3(3), 403–407	GW640385	Lorazepam
3(3), 367–378	Dutasteride	3(1), 79–88	3(1), 153–162
Cyclophosphamide	3(3), 397–400	Herstatin	Low-density lipoprotein
3(1), 97–112	Dx Spansule® (see psychostimulants)	3(1), 97–112	3(3), 329–333
3(1), 139–151	Echinocardins	Hexetidine	Luciferase
Cyclosporine	3(1), 39–54	3(1), 139–151	3(1), 97–112
3(1), 39–54	Epidermal growth factor receptor	IFN–2α	Macrolides
3(1), 139–151	3(3), 421–430	3(1), 139–151	3(3), 359–365
3(3), 439–450	Erlotinib	IFN–α?	Macula
3(4), 450	3(3), 421–430	3(1), 139–151	3(3), 431–438
Cylcosporin A	Erythromycin	Imipramine	Malonedialdehyde
3(1), 139–151	3(4), 527–534	3(1), 19–38	3(1), 113–117
3(3), 367–378	Etanercept	Immunoglobulin	Mannitol
Dalteparin	3(1), 139–151	3(1), 69–78	3(1), 97–112
3(4), 461–474	3(3), 379–387	Indinavir	Mepivacaine
Darifenacin	3(3), 439–450	3(1), 79–88	3(1), 139–151
3(4), 485–494	Etoposide	Infliximab	Metadate CD® (see psychostimulants)
Deferasirox	3(1), 97–112	3(1), 139–151	Metformin
3(4), 453–460		3(3), 439–450	3(3), 339–348

APPENDICES

Methotrexate	Paclitaxel	Scopolamine	Superparamagnetic iron oxide nanoparticles
3(1), 97–112	3(1), 1–3	3(4), 495–498	3(1), 97–112
3(1), 139–151	3(1), 97–112	Second-generation cephalosporin	Tacrolimus
3(3), 379–387	3(3), 367–378	3(1), 163–174	3(1), 39–54
3(3), 439–450	Pandropazole	Selective estrogen–receptor modulator	Tamoxifen
3(4), 450	3(4), 495–498	3(3), 403–407	3(1), 19–38
3(4), 495–498	Paroxetine	Selective serotonin reuptake inhibitor	3(3), 403–407
3(4), 535–545	3(1), 19–38	3(3), 421–430	Tarceva® (see Erlotinib)
Methylin ER® (see psychostimulants)	3(1), 93–96	Selective norepinephrine reuptake inhibitor	Taxane
Methylphenidate	3(1), 153–162	3(1), 19–38	3(3), 367–378
3(1), 19–38	Paxil® (see paroxetine)	3(1), 153–162	Taxol® (see Paclitaxel)
Methylphenidate SR® (see psychostimulants)	PD153035	Selegiline	Taxotere
3(3), 421–430	3(3), 421–430	3(3), 349–357	3(1), 97–112
Methylprednisolone	Penicillins	Serotonin selective re–uptake inhibitors	Technosphere® (see inhaled human insulin)
3(1), 139–151	3(1), 163–174	3(1), 93–96	Tedisimile
Methypatch® (see psychostimulants)	Phenobarbital	3(3), 421–430	3(4), 445–448
Micafungin	3(1), 153–162	Sertraline	Tegaserod
3(1), 39–54	Piracetam	3(1), 153–162	3(4), 475–484
MicroDose (see inhaled human insulin)	3(1), 93–96	Several second-generation protease inhibitors	Tenex® (see guanfacine)
Microsphere formulation	Pioglitazone	3(1), 79–88	Testosterone
3(3), 359–365	3(3), 329–333	SGN–15	3(3), 397–400
Modafinil	Provigil® (see modafinil)	3(1), 97–112	Tetracaine
3(3), 389–396	PL100	Silver nitrate	3(1), 139–151
Mozenavir	3(1), 79–88	3(1), 139–151	Tetracycline
3(1), 79–88	Posaconazole	Sirolimus	3(1), 139–151
Myocardial infarction	3(1), 39–54	3(1), 1–3	Tetraethoxypropane
3(3), 329–333	Prednisolone	Sodium oxybate	3(1), 113–117
Myoscint®	3(1), 139–151	3(3), 389–396	Tetrahydrofuran
3(4), 535–545	Prednisone	Sodium thiosulfate	3(1), 79–88
Narcolepsy	3(1), 97–112	3(1), 97–112	Thalidomide
3(3), 389–396	Propantheline	Solifenacin	3(1), 139–151
Nateglinide	3(4), 485–494	3(4), 485–494	Thrombocytopenia
3(3), 329–333	Propafenone	Somatropin	3(3), 367–378
Nefazodone	3(4), 445–448	3(1), 55–67	Third-generation cephalosporins
3(1), 153–162	Psoralen	Sotalol	3(1), 163–174
Nelfinavir	3(3), 439–450	3(1), 125–138	Tipranavir
3(1), 79–88	Psychostimulants	SPI–70095	3(1), 79–88
Nucleoside	3(1), 19–38	3(1), 79–88	TMC 126
3(1), 79–88	Quinazoline	Spiros® (see inhaled human insulin)	3(1), 79–88
Non–nucleoside inhibitors of reverse transcriptase	3(3), 421–430	SPSS®	Tofranil® (see imipramine)
3(1), 79–88	Recombinant human growth hormone	3(3), 409–412	Topoisomerase I agents
Ondansetron	3(1), 55–67	Statins	3(1), 97–112
3(1), 97–112	Resistant–Repellent™ (see SPI–70095)	3(1), 125–138	Topoisomerase II agents
Orabase	Rifampin	3(4), 445–448	3(1), 97–112
3(1), 139–151	3(1), 39–54	Strattera® (see atomoxetine hydrochloride)	Tolterodine
Oral retinoids	Ritalin LA® (see psychostimulants)	Streptodornase	3(4), 485–494
3(3), 439–450	Ritalin SR® (see psychostimulants)	3(1), 163–174	Transient ischemic attack
Orally disintegrating tablet	Ritalin® (see methylphenidate)	Streptodornase–a	3(3), 329–333
3(3), 349–357	Ritonavir	3(1), 163–174	Transitional cell carcinoma
Ovalbumin	3(1), 79–88	Streptokinase	3(3), 421–430
3(1), 69–78	Rituximab	3(1), 163–174	Trastuzumab
Oxaliplatin	3(4), 535–545	Sucralfate	3(1), 97–112
3(1), 97–112	Rosiglitazone	3(1), 139–151	3(3), 421–430
Oxazolone	3(3), 339–348		3(4), 449
3(1), 69–78	Rosuvastatin		Traumatic brain injury
Oxybutynin	3(3), 329–333		3(3), 413–419
3(4), 485–494	Saquinavir		
	3(1), 79–88		

Trazodone	Tricyclic antidepressants	3(1), 163–174	Voriconazole
3(1), 93–96	3(3), 401–402	Venlafaxine	3(1), 39–54
3(1), 153–162	Trospium	3(1), 153–162	Welbutrin® (see bupropion)
Triamcinolone acetonide	3(4), 485–494	Venlafaxine	ZD1839
3(1), 139–151	Tween 80	3(1), 19–38	3(3), 421–430
Trichloroacetic acid	3(3), 367–378	Verapamil	Ximelagatran
3(1), 113–117	Tygacil®	3(1), 125–138	3(4), 461–474
Tricyclic antidepressants	3(4), 449	Verteporfin	Zelnorm®
3(1), 19–38	Tyr-gly-gly	3(3), 431–438	3(4),
Tricyclics	3(1), 69–78	Vincristine	Zydis® (see Selegiline)
3(1), 153–162	Valsartan	3(1), 97–112	Zyvox
Tris base	3(3), 329–333	Vinorelbine	3(4), 521–526
3(1), 113–117	Vancomycin	3(1), 97–112	